Organogenesis Holdings Inc.
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
ORGO$0.94+3.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)
(amounts in thousands, except share and per share amounts)
| Three Months EndedSeptember 30, | Nine Months EndedSeptember 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Revenue: | ||||
| Net product revenue | $150,487 | $115,177 | $337,959 | $355,387 |
| Grant income | 377 | — | 603 | — |
| Total revenue | 150,864 | 115,177 | 338,562 | 355,387 |
| Operating expenses: | ||||
| Cost of goods sold | 36,251 | 26,796 | 87,604 | 84,690 |
| Selling, general and administrative | 79,743 | 71,795 | 226,062 | 220,657 |
| Research and development | 13,221 | 10,344 | 34,256 | 38,741 |
| Write-down to fair value for asset held for sale | 922 | — | 9,235 | — |
| Impairment of property and construction | — | — | — | 18,842 |
| Write-down of capitalized internal-use software costs | — | — | — | 3,959 |
| Total operating expenses | 130,137 | 108,935 | 357,157 | 366,889 |
| Income (loss) from operations | 20,727 | 6,242 | (18,595) | (11,502) |
| Other income (expense), net: | ||||
| Interest income (expense), net | 415 | (471) | 2,045 | (1,605) |
| Other income, net | 18 | 52 | 93 | 47 |
| Total other income (expense), net | 433 | (419) | 2,138 | (1,558) |
| Net income (loss) before income taxes | 21,160 | 5,823 | (16,457) | (13,060) |
| Income tax benefit | 407 | 6,508 | 9,789 | 6,248 |
| Net income (loss) and comprehensive income (loss) | 21,567 | 12,331 | (6,668) | (6,812) |
| Accretion of redeemable convertible preferred stock to redemption value | (140) | — | (390) | — |
| Cumulative dividend on redeemable convertible preferred stock | (2,734) | — | (8,042) | — |
| Undistributed earnings allocated to participating redeemable convertible preferred stock | (4,168) | — | — | — |
| Net income (loss) attributable to common stockholders | $14,525 | $12,331 | $(15,100) | $(6,812) |
| Net income (loss) per share: | ||||
| Basic | $0.11 | $0.09 | $(0.12) | $(0.05) |
| Diluted | $0.11 | $0.09 | $(0.12) | $(0.05) |
| Weighted-average common shares outstanding: | ||||
| Basic | 126,881,709 | 132,575,301 | 126,679,109 | 132,342,203 |
| Diluted | 130,848,995 | 133,926,755 | 126,679,109 | 132,342,203 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.